PMID- 31782677
OWN - NLM
STAT- MEDLINE
DCOM- 20210121
LR  - 20210121
IS  - 1941-837X (Electronic)
IS  - 1369-6998 (Linking)
VI  - 23
IP  - 4
DP  - 2020 Apr
TI  - Economic evaluation of olmesartan/amlodipine fixed-dose combination for 
      hypertension treatment in China.
PG  - 394-400
LID - 10.1080/13696998.2019.1699799 [doi]
AB  - Objectives: To evaluate the cost-effectiveness of olmesartan/amlodipine 
      fixed-dose combination vs olmesartan and amlodipine free combination, amlodipine 
      single drug, and valsartan/amlodipine fixed-dose combination in the treatment of 
      hypertensive patients from payer perspective in China.Methods: A Markov model was 
      constructed, which included five health states of hypertensive patients who are 
      aged 35-84 years at baseline and free of cardiovascular disease. Clinical data 
      were obtained from a network meta-analysis. Epidemiology data, adverse events 
      (AEs), cost, and utility data were obtained from the literature. The cost 
      associated with AEs was estimated based on the cost of same symptoms of 
      hypertensive patients in an electric medical record database. The model projected 
      quality-adjusted life years (QALYs) gained, total costs per patient in a 20-year 
      time horizon, and incremental cost-effectiveness ratios. Probability sensitivity 
      analyses (PSA) and one-way sensitivity analyses were conducted for the main 
      parameters to test the robustness of the model.Results: Compared to olmesartan 
      and amlodipine free combination, amlodipine, and valsartan/amlodipine fixed-dose 
      combination, treatment with olmesartan/amlodipine fixed-dose combination led to 
      fewer CVD events and deaths; resulted in an incremental cost of  yen-5,439 
      ($-791.36),  yen6,530 ($950.09), and  yen-1,019 ($-148.26) and gained additional QALYs 
      of 0.052, 0.094, and 0.037 per patient, respectively. Compared with olmesartan 
      and amlodipine free combination and valsartan/amlodipine fixed-dose combination, 
      olmesartan/amlodipine fixed-dose combination was dominant. Compared with 
      amlodipine alone, the incremental cost-effectiveness ratios were below the WHO 
      recommended cost-effectiveness threshold, indicating the olmesartan/amlodipine 
      fixed-dose combination was a cost-effective option for hypertensive patients in 
      China. The 10-years' time horizon scenario analysis showed similar results to the 
      20-years' time horizon. Probabilistic sensitivity analysis and one-way 
      sensitivity analyses showed the robustness of the model results.Conclusions: 
      Olmesartan/amlodipine fixed-dose combination confers better health outcomes and 
      costs less compared with olmesartan and amlodipine free combination and 
      valsartan/amlodipine fixed-dose combination, and is cost-effective compared to 
      amlodipine for hypertension treatment in China.
FAU - Ren, Maodong
AU  - Ren M
AD  - Shanghai Centennial Scientific Co., Ltd, Shanghai, China.
FAU - Xuan, Dennis
AU  - Xuan D
AD  - Gillings Global School of Public Health, The University of North Carolina at 
      Chapel Hill, Chapel Hill, USA.
FAU - Lu, Yongji
AU  - Lu Y
AD  - Shanghai Centennial Scientific Co., Ltd, Shanghai, China.
FAU - Fu, YuYan
AU  - Fu Y
AD  - Health Economic Research Institute, Sun Yat-Sen University, Guangzhou, China.
FAU - Xuan, Jianwei
AU  - Xuan J
AD  - Health Economic Research Institute, Sun Yat-Sen University, Guangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20200125
PL  - England
TA  - J Med Econ
JT  - Journal of medical economics
JID - 9892255
RN  - 0 (Imidazoles)
RN  - 0 (Tetrazoles)
RN  - 1J444QC288 (Amlodipine)
RN  - 8W1IQP3U10 (olmesartan)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Amlodipine/*administration & dosage/economics
MH  - China
MH  - Cost-Benefit Analysis
MH  - Databases, Factual
MH  - Drug Therapy, Combination/*economics
MH  - Female
MH  - Humans
MH  - Hypertension/*drug therapy
MH  - Imidazoles/*administration & dosage/economics
MH  - Male
MH  - Medical Records
MH  - Middle Aged
MH  - Tetrazoles/*administration & dosage/economics
OTO - NOTNLM
OT  - Anti-hypertensives
OT  - I11
OT  - I15
OT  - cardiovascular disease
OT  - cost-effectiveness analysis
OT  - fixed-dose combination
EDAT- 2019/11/30 06:00
MHDA- 2021/01/22 06:00
CRDT- 2019/11/30 06:00
PHST- 2019/11/30 06:00 [pubmed]
PHST- 2021/01/22 06:00 [medline]
PHST- 2019/11/30 06:00 [entrez]
AID - 10.1080/13696998.2019.1699799 [doi]
PST - ppublish
SO  - J Med Econ. 2020 Apr;23(4):394-400. doi: 10.1080/13696998.2019.1699799. Epub 2020 
      Jan 25.